Travis Taylor, MD
Cardiovascular Disease · Corpus Christi, TXNPI 1386969343
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,129 of the $14,100 with a category attached, or 71.8%. 29 manufacturers reported payments, led by Abbott at 36.9% of the total. Reporting peaked in 2019 at $4,806 and has fallen 71.0% since, to $1,392 in 2025.
Across 379 payments — averaging $37.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Medtronic$3K
- Boston Scientific$1K
- Johnson & Johnson$972
- Philips North America LLC$764
- Abiomed$682
- plus $3K from 23 others
Across 15 payments — averaging $45,411 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$510K
- AstraZeneca$171K
What the payments were for
- Consulting fees$751%
- Travel & lodging$3,89628%
- Food & beverage$10,12972%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 73 | $5,205 |
| Medtronic(2 entities) | 95 | $2,521 |
| Boston Scientific | 9 | $1,248 |
| Johnson & Johnson | 51 | $972 |
| Philips North America LLC | 8 | $764 |
| Abiomed | 16 | $682 |
| Pfizer | 25 | $362 |
| Novartis | 16 | $362 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $226 |
| AstraZeneca | 14 | $222 |
| Terumo Medical Corporation | 2 | $185 |
| E.r. Squibb & Sons, L.L.C. | 9 | $159 |
| Actelion Pharmaceuticals US, Inc. | 2 | $157 |
| Esperion Therapeutics, Inc. | 6 | $155 |
| Amgen | 8 | $130 |
| Merck | 8 | $126 |
| W. L. Gore & Associates, Inc. | 4 | $113 |
| Celonova Biosciences, Inc. | 1 | $98 |
| Boehringer Ingelheim | 4 | $72 |
| Recor Medical Inc | 1 | $70 |
| Cardiovascular Systems Inc. | 3 | $54 |
| Cvrx, Inc. | 3 | $54 |
| Edwards Lifesciences | 3 | $45 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Shockwave Medical, Inc | 1 | $25 |
| Irhythm Technologies, Inc. | 1 | $22 |
| Biotronik Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$1,682
- Mitra Clip system$1,072
- Watchman$1,044
- COREVALVE EVOLUT R$779
- IGT D Coronary$599
- Impella$243
- XARELTO$133
- UPTRAVI$121
- OPSUMIT$121
- CoreValve Evolut$109
How this compares
$14,100 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 426 | $491,886 |
| EntrestoSacubitril/Valsartan | 240 | $278,981 |
| XareltoRivaroxaban | 110 | $135,773 |
| JardianceEmpagliflozin | 86 | $88,225 |
| FarxigaDapagliflozin Propanediol | 44 | $56,130 |
| Metoprolol Succinate | 598 | $7,662 |
| Atorvastatin Calcium | 755 | $6,554 |
| Valsartan | 240 | $6,107 |
| Praluent PenAlirocumab | 11 | $5,285 |
| Chlorthalidone | 240 | $5,109 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 338 | $4,009 |
| Spironolactone | 303 | $3,361 |
| ClopidogrelClopidogrel Bisulfate | 369 | $3,100 |
| Ranolazine ErRanolazine | 18 | $3,046 |
| Amlodipine Besylate | 512 | $2,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $362 | $491,886426 claims |
| NovartisEntresto | $362 | $278,981240 claims |
| Johnson & JohnsonXarelto | $972 | $135,773110 claims |
| Boehringer IngelheimJardiance | $72 | $88,22586 claims |
| AstraZenecaFarxiga | $222 | $56,13044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Corpus Christi
- Thomas AlexanderCorpus Christi$95K
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.